Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 10;7(9):2591-2595.
doi: 10.1021/acsinfecdis.1c00237. Epub 2021 Aug 26.

Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease

Affiliations

Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease

Elizabeth A MacDonald et al. ACS Infect Dis. .

Abstract

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), is an ideal target for pharmaceutical inhibition. Mpro is conserved among coronaviruses and distinct from human proteases. Viral replication depends on the cleavage of the viral polyprotein at multiple sites. We present crystal structures of SARS-CoV-2 Mpro bound to two viral substrate peptides. The structures show how Mpro recognizes distinct substrates and how subtle changes in substrate accommodation can drive large changes in catalytic efficiency. One peptide, constituting the junction between viral nonstructural proteins 8 and 9 (nsp8/9), has P1' and P2' residues that are unique among the SARS-CoV-2 Mpro cleavage sites but conserved among homologous junctions in coronaviruses. Mpro cleaves nsp8/9 inefficiently, and amino acid substitutions at P1' or P2' can enhance catalysis. Visualization of Mpro with intact substrates provides new templates for antiviral drug design and suggests that the coronavirus lifecycle selects for finely tuned substrate-dependent catalytic parameters.

Keywords: Mpro; SARS-CoV-2; protease; virology.

PubMed Disclaimer

Conflict of interest statement

Mark Namchuk is the recipient of funding from AbbVie. The funding did not contribute to this work.

Figures

Figure 1.
Figure 1.
Viral Mpro substrates. (A) Protein sequence alignment of the 11 SARS-CoV-2 Mpro cleavage sites required for maturation of SARS-CoV2. (B) Protein sequence alignment of nsp8/9 Mpro cleavage sites from representative coronaviruses.
Figure 2.
Figure 2.
Differential recognition of nsp4/5 and nsp8/9 substrates by Mpro. Identical views of nsp4/5 (A) and nsp8/9 (B) substrates in the MproCys145Ala active site. Substrate peptide P and P′ residues are labeled with colored numbers. Key Mpro residues mentioned in the text are labeled. Conserved hydrogen bonds enabling Mpro recognition of substrate mainchain and P1 Gln side chain atoms are shown as white dashed lines. Hydrogen bonds that differ between the complex with nsp4/5 and that with nsp8/9 are shown in green and magenta, respectively. Mpro Asn142 and Gln189 contact both substrate through bound water molecules, and the resulting networks of hydrogen bonds differ between the two substrates.
Figure 3.
Figure 3.
Steric effects that influence substrate recognition and Mpro activity. Spheres show positions of atoms dictating shape complementarity between Mpro subsites and nsp4/5 (A), nsp8/9 (B), and nsp5 (C; acyl-enzyme intermediate, PDB 7KHP). Labels show Mpro subsites and the distance between Mpro Met49 and Asn142 (thioether to amide nitrogen).

References

    1. Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763–1767. - PubMed
    1. Hilgenfeld R, From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014, 281, 4085–4096. - PMC - PubMed
    1. Zhang L; Lin D; Sun X; Curth U; Drosten C; Sauerhering L; Becker S; Rox K; Hilgenfeld R, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 2020, 368, 409–412. - PMC - PubMed
    1. Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA, Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses 2021, 13. - PMC - PubMed
    1. Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J, Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 2020, 30, 678–692. - PMC - PubMed

Publication types